{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for vitamin root_names_stdName in Standardized Name (approximate match)
Status:
Investigational
Source:
NCT00357357: Phase 2 Interventional Completed Alzheimer's Disease
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:gemlapodect [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03387215: Phase 1/Phase 2 Interventional Completed Heart Failure, Systolic
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT01221259: Phase 1 Interventional Completed Alzheimer's Disease
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02983617: Phase 2 Interventional Completed Chronic Lymphocytic Leukemia
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Entospletinib (GS-9973) is an adenosine triphosphate competitive inhibitor of Syk that disrupts kinase activity, which is currently in clinical trials for multiple B-cell malignancies. The most common treatment-emergent serious adverse events included dyspnea, pneumonia, febrile neutropenia, dehydration, and pyrexia.
Status:
Investigational
Source:
NCT03257592: Phase 1 Interventional Terminated Schizophrenia
(2010)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:remeglurant [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Remeglurant is a selective antagonist of subtype 5 metabotropic glutamate receptors (mGluR5). mGluR5 antagonists have a modulatory role in the control of glutamatergic neurotransmission. This drug was developed for treatment in drug-induced dyskinesia (an involuntary movement disorder). A phase 1 trial was conducted but no further development has been reported since 2016.
Status:
Investigational
Source:
NCT03519230: Phase 3 Interventional Active, not recruiting Ovarian Cancer
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00333411: Phase 2 Interventional Completed Psoriasis
(2006)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:gartisertib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
